Anzeige
❌
Mehr »
Donnerstag, 29.10.2026 - Börsentäglich über 12.000 News
US-Bann naht: Pentagon sperrt China-Metalle - dieser Nickel-Explorer reagiert
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GB

WKN: A3DCSM | ISIN: GB00BP2C3V08 | Ticker-Symbol: WQ5
Frankfurt
29.10.26 | 08:55
0,017 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENFLOW BIOSCIENCES PLC Chart 1 Jahr
5-Tage-Chart
GENFLOW BIOSCIENCES PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0210,02315:59

Aktueller Chart GENFLOW BIOSCIENCES Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
GENFLOW BIOSCIENCES PLC-Investoren interessieren sich auch für diese Wertpapiere
XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen. 1. US88025U1097 10X GENOMICS INC 2. NL0000852564 AALBERTS NV 3. SE0016589188 ELECTROLUX AB 4. SE0000115446...
► Artikel lesen
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected...
► Artikel lesen
Morningstar, Inc.: Morningstar Completes Rebrand of CRSP Market Indexes to Morningstar Market Indexes Indexes underpinning more than $3 trillion in investor assets move under the Morningstar brand, expanding visibility and supporting future growth Morningstar, Inc. (NASDAQ: MORN), a leading provider...
► Artikel lesen
DelveInsight Business Research, LLP: Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsightSevere Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight The severe hypertriglyceridemia...
► Artikel lesen
Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...
► Artikel lesen
Genentech, Ionis Reveal Positive Interim Data From Phase III Sefaxersen Study In IgA NephropathySOUTH SAN FRANCISCO (dpa-AFX) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW), and partner Ionis Pharmaceuticals, Inc. (IONS) announced Wednesday positive...
► Artikel lesen
PacBio Appoints Mark Van Oene as President and Chief Executive OfficerMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,...
► Artikel lesen
PacBio Announces Second Quarter 2026 Financial ResultsMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0...
► Artikel lesen
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega systemMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry...
► Artikel lesen